Seikagaku Corporation revised earnings guidance for the fiscal year ending March 31, 2019. For the year, the company now expects net sales of JPY 28,350 million, operating income of JPY 950 million, net income attributable to owners of parent of JPY 2,200 million and net income per share of JPY 38.97 compared to previous forecast of net sales of JPY 28,100 million, operating income of JPY 400 million, net income attributable to owners of parent of JPY 1,700 million and net income per share of JPY 30.11. Net sales are projected to slightly exceed the previous forecast due to the positive impact of exchange rates accompanying yen depreciation and sales increases from the LAL business and bulk products. This result comes despite a greater-than-expected decline in sales of domestic pharmaceuticals. With regard to earnings, although R&D expenses are projected to be slightly higher than previous forecast, operating income, ordinary income, and net income attributable to owners of parent are expected to exceed the previous forecasts due to a decrease in selling, general and administrative expenses because of cost-cutting measures and other factors.